Delivery Order SPE2DB25D3306-SPE2DB26FUALG
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,519.00 to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Scemblix 40 mg tablets in quantities of 60 units. This firm fixed-price, competitively awarded contract carries an ultimate completion date of September 26, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for the supply of Scemblix 40 mg tablets (60-count units) under a firm fixed-price contract. The order, issued on August 22, 2025, with an ultimate completion date of September 15, 2025, represents a competitively awarded, non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $26,519.00 to AmerisourceBergen Drug Corp for supply of Scemblix 40 mg tablets (60 count) on September 5, 2025, with completion targeted for September 26, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,637.88 to AmerisourceBergen Drug Corp for the supply of Scemblix 20 mg tablets (60-count units) under a firm fixed-price contract type. The award, issued on July 21, 2025, with an ultimate completion date of August 11, 2025, represents a non-competitive delivery against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. Performance will take place at the vendor's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for 60 units of Scemblix 40 mg tablets, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a single transaction under the company's larger pharmaceutical supply relationship with the federal government. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major...
- The Defense Logistics Agency (DLA) awarded a $13,259.50 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Scemblix 40 mg tablets (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 3, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $13,259.50 firm fixed price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Scemblix 40 mg, a pharmaceutical product for federal medical supply needs. The contract was competitively awarded without a set-aside designation and is scheduled for completion by October 14, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military and veteran healthcare systems through the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for 60 tablets of Scemblix 40 mg, a pharmaceutical product, with completion scheduled for July 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Scemblix 40 mg tablets (60-count units) with a contract ceiling value of $39,778.50. This is a firm fixed-price delivery order with no set-aside designation, representing a competitive award to the pharmaceutical distributor. The contract is set to be completed by September 17, 2025, and performance will take place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency has awarded a delivery order valued at $26,519.00 to AmerisourceBergen Drug Corp for the supply of Scemblix 40 mg tablets (60-count units), with a completion deadline of September 26, 2025. This competitive, non-set-aside contract reflects firm fixed pricing and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The contract will be performed at the contractor's corporate office...
- SPE2DB25D3306Indefinite Delivery Contract
- SPE2DB25D3306-SPE2DB26FUALGDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of Scemblix 40 mg medication, with a contract ceiling value of $13,259.50. This firm fixed-price delivery order, awarded October 14, 2025, with an ultimate completion date of November 4, 2025, represents a non-competitive set-aside contract issued under DLA's existing procurement framework. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, leveraging its established position as a major pharmaceutical distributor for federal medical procurement. This delivery order is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This comprehensive IDC vehicle enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs globally. The current award for Scemblix, a prescribed medication, reflects the company's ongoing role as a critical vendor providing brand-name medications, generics, vaccines, and specialized medical commodities across multiple therapeutic domains to the Department of Defense and affiliated healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.3k | 10/14/25 |